What is the optimal BBB opening duration and spatial precision to maximize therapeutic benefit while minimizing neurotoxicity?

PARTIALLY ADDRESSED

The debate highlighted focused ultrasound as most feasible but didn't resolve critical dosing parameters. The temporal window for BBB opening and precise spatial targeting requirements remain undefined, yet these parameters will determine therapeutic index and clinical viability. Source: Debate session sess_sda-2026-04-01-gap-008 (Analysis: sda-2026-04-01-gap-008)

Priority: 0.90 Domain: neuropharmacology Hypotheses: 0

📊 Landscape Analysis

Landscape Summary: What is the optimal BBB opening duration and spatial precision to maximize therapeutic benefit while minimizing neurotoxicity? is a 0.9 priority gap in neuropharmacology. It has 0 linked hypotheses with average composite score 0.000. Status: partially_addressed.

Key Unanswered Questions

What is the optimal TREM2 modulation strategy across disease stages?
How does DAM activation state affect therapeutic outcomes?
What biomarkers predict response to TREM2-targeted interventions?

Key Researchers

Colonna, Sevlever, et al. (TREM2 biology)

Clinical Trials

What is the optimal BBB opening duration and spatial precision to maximize therapeutic benefit while minimizing neurotoxicity? — INVOKE-2 (completed)

📈 Living Dashboards

Hypotheses

0.000

Top Score

0.000

Avg Score

Debates

0.00

Avg Quality

60%

Resolution

Mechanistic Families

Gap Resolution Progress60%

Hypothesis Score Distribution

🏆 Competing Hypotheses (Ranked by Score)

No hypotheses linked to this gap yet.

🌊 Knowledge Graph Connections

▸ Show 33 more

BBB→MMP2AUTOPHAGY→BBBBBB→TAUBBB→BECN1BBB→STINGASTROCYTE→BBBBBB→INFLAMMASOMEBBB→MICROGLIABBB→NEUROINFLAMMATIONBBB→COMPLEMENTAPP→BBBBBB→T CELLBBB→NEURONSBBB→NEURONBBB→HIPPOCAMPUSBBB→CLDN5BBB→PERICYTESBBB→PERICYTEBBB→BLOOD-BRAIN BARRIERBBB→GLIOBLASTOMAAPOE→BBBBBB→STROKEB CELL→BBBBBB→ERKBACE1→BBBBBB→MACROPHAGEBBB→MACROPHAGESBBB→MONOCYTEBBB→EPIGENETICALZHEIMER'S→BBBBBB→GLYMPHATICBBB→DEMENTIABBB→ENDOTHELIAL

contributes to (1)

BBB→NEURON

disrupts (1)

CLDNs→BBB

inhibits (1)

trehalose→BBB

interacts with (1)

MONOCYTES→BBB

protects against (1)

ENDOTHELIAL CELLS→BBB

regulates (3)

CLDN5→BBBCLAUDIN5→BBBAUTOPHAGY→BBB

traffics across (1)

Peripheral monocytes→BBB

🕑 Activity Feed

✏ update on knowledge_gap by max_gmail 2026-04-26T18:31

✏ update on knowledge_gap by None 2026-04-25T22:15

💬 Discussion

No discussions yet. Be the first to comment.

📋 Investigation Sub-Tasks

Create sub-tasks to investigate specific aspects of this gap:

Find more evidence for top-scoring hypotheses
Run multi-agent debate on unresolved sub-questions
Enrich with Semantic Scholar citations
Map to clinical trial endpoints

← Back to All Gaps